Insider Buying: Enovis (NYSE:ENOV) Insider Acquires 1,200 Shares of Stock

by · The Markets Daily

Enovis Corporation (NYSE:ENOV – Get Free Report) insider Oliver Engert purchased 1,200 shares of the company’s stock in a transaction on Thursday, June 11th. The shares were purchased at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the completion of the transaction, the insider directly owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. This represents a 2.37% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Oliver Engert also recently made the following trade(s):

  • On Wednesday, June 10th, Oliver Engert purchased 1,000 shares of Enovis stock. The shares were purchased at an average cost of $23.00 per share, for a total transaction of $23,000.00.
  • On Monday, June 1st, Oliver Engert acquired 1,000 shares of Enovis stock. The stock was bought at an average cost of $22.22 per share, for a total transaction of $22,220.00.

Enovis Stock Performance

Shares of ENOV traded down $0.89 during trading hours on Monday, hitting $20.91. The company had a trading volume of 845,447 shares, compared to its average volume of 1,025,950. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of -1.05 and a beta of 1.38. The business has a fifty day moving average of $24.00 and a 200-day moving average of $24.50. Enovis Corporation has a 12 month low of $20.55 and a 12 month high of $36.82. The company has a quick ratio of 1.05, a current ratio of 2.04 and a debt-to-equity ratio of 0.87.

Enovis (NYSE:ENOV – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, beating the consensus estimate of $0.82 by $0.07. The company had revenue of $589.15 million for the quarter, compared to analyst estimates of $572.02 million. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The company’s revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.81 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities analysts anticipate that Enovis Corporation will post 3.65 EPS for the current fiscal year.

Hedge Funds Weigh In On Enovis

Hedge funds have recently bought and sold shares of the business. Arax Advisory Partners bought a new position in Enovis during the fourth quarter worth about $29,000. EverSource Wealth Advisors LLC increased its holdings in Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after buying an additional 707 shares during the period. GAMMA Investing LLC increased its holdings in Enovis by 353.5% in the 4th quarter. GAMMA Investing LLC now owns 1,855 shares of the company’s stock valued at $49,000 after buying an additional 1,446 shares during the period. Danske Bank A S bought a new position in Enovis in the 3rd quarter valued at about $64,000. Finally, iSAM Funds UK Ltd bought a new position in Enovis in the 3rd quarter valued at about $80,000. 98.45% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on ENOV shares. Zacks Research lowered shares of Enovis from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 1st. Needham & Company LLC increased their price objective on shares of Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. BTIG Research reaffirmed a “buy” rating and set a $39.00 price target on shares of Enovis in a research report on Friday, May 22nd. Evercore reaffirmed an “outperform” rating and set a $36.00 price target on shares of Enovis in a research report on Friday, May 8th. Finally, Wells Fargo & Company lowered their price target on shares of Enovis from $42.00 to $40.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $44.50.

Check Out Our Latest Stock Analysis on Enovis

Enovis Company Profile

(Get Free Report)

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.

Read More